{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"UCYSPYOYJNVCAI-FCHUYYIVSA-N","prefName":"Cannabidiol diacetate","symbol":"CBD-DA","iupacName":"[3-acetyloxy-2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenyl] acetate","aliases":["cannabidiol diacetate","CBD diacétate","CBD-DA","ALL00142","diacétate de CBD"],"cas":null,"pubchemCid":"15139512","chebiId":null,"smiles":"CCCCCC1=CC(=C(C(=C1)OC(=O)C)[C@@H]2C=C(CC[C@H]2C(=C)C)C)OC(=O)C","molecularFormula":"C25H34O4","molecularWeight":398.5,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/15139512"}},"classification":{"family":"semisynthetique","familyLabel":"Semi-synthetic cannabinoid","origin":"semisynthetic","originLabel":"Semi-synthétique","structuralClassFr":"Diester acétique du cannabidiol. Le squelette reste celui du cannabidiol, avec son cycle résorcinol portant la chaîne pentyle et son cycle terpénique porteur du groupement isopropényle, dans la configuration 1R,6R. Les deux fonctions phénol sont acétylées, ce qui supprime les donneurs de liaison hydrogène et augmente nettement la lipophilie. Cette molécule appartient à la même logique chimique que les autres esters et carbonates de cannabidiol développés pour l'administration transdermique."},"originSynthesis":{"heading":"Route of preparation (chemical process)","summaryFr":"No plant route. The diacetate is the acetic diester of cannabidiol: the two phenol functions of the resorcinol ring are esterified by acetic acid, which removes the two free hydroxyls and strongly increases the lipophilicity of the molecule. It is described here by chemical class only.","originNote":"A semi-synthetic compound, absent from cannabis. It is obtained by acetylation of the two hydroxyl groups of cannabidiol. It is encountered today in two distinct contexts: pharmaceutical research on transdermal prodrugs, and grey-market products where it is added outside any regulatory framework.","discovered":"Le composé apparaît dans les travaux de chimie médicinale sur les dérivés du cannabidiol, où l'acétylation des deux fonctions phénol a été explorée comme voie de promédicament. La société AllTranz, devenue Zynerba, a développé dans cette logique une série d'esters et de carbonates du cannabidiol pour l'administration transdermique, dont le diacétate. Le composé a depuis été retrouvé comme constituant de produits du marché gris, notamment des liquides pour cigarette électronique et des aliments infusés."},"pharmacology":{"summaryFr":"Cannabidiol diacetate is the acetic diester of cannabidiol, in which the two phenol functions of the resorcinol ring are masked by acetyl groups. The logic is that of a prodrug: cannabidiol distributes rapidly into adipose tissue and undergoes substantial first-pass metabolism carried by CYP3A and CYP2C, so that increasing its lipophilicity and protecting its phenols may favourably modify its kinetics, the acetate groups then being cleaved by esterases to restore the active molecule. That is the route explored by the company AllTranz, which became Zynerba, in a series of derivatives intended for transdermal administration. The compound has since migrated out of the laboratory: it has been identified as a constituent of grey-market products, electronic cigarette liquids and infused foods. That displacement deserves to be flagged, because a derivative designed for controlled transdermal absorption has been the subject of no assessment for inhalation, a route that raises its own questions, notably about the fate of heated esters. No pharmacokinetic or human safety data are published for this compound.","receptorSummaryFr":"A presumed prodrug of cannabidiol: the expected activity is that of the molecule restored after deacetylation, and not that of the diester itself, whose two masked phenol functions remove the hydrogen-bonding interactions that take part in the recognition of cannabidiol by its targets. The cannabidiol released is itself only a weak ligand of CB1 and CB2 receptors, its activity passing mainly through other targets. No affinity data specific to the diacetate are published.","binding":[{"target":"CB1","efficacy":"partial_agonist","relativeActivity":5,"reported":null,"confidence":"low"},{"target":"CB2","efficacy":"partial_agonist","relativeActivity":5,"reported":null,"confidence":"low"}],"references":[{"label":"Chimie médicinale des dérivés synthétiques et naturels du cannabidiol (revue, Frontiers in Pharmacology 2017)","pmid":null,"doi":null,"url":"https://www.frontiersin.org/articles/10.3389/fphar.2017.00422/full"},{"label":"PubChem CID 15139512 : diacétate de cannabidiol","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/15139512"}]},"pharmacokinetics":"Aucune donnée humaine publiée. Le rationnel du promédicament repose sur la lipophilie accrue, censée favoriser le passage transdermique, et sur le clivage ultérieur des esters par les estérases cutanées et plasmatiques pour libérer le cannabidiol. Cette hypothèse n'a pas été vérifiée par des données pharmacocinétiques accessibles pour le diacétate, et rien n'est documenté pour la voie inhalée, qui est pourtant celle par laquelle le composé circule dans les produits du marché gris.","metabolism":"Le clivage attendu est l'hydrolyse des deux liaisons ester par les estérases, restituant le cannabidiol et l'acide acétique. Le cannabidiol ainsi libéré suit ensuite son métabolisme propre, dominé par les CYP3A et CYP2C, avec formation du 7-hydroxycannabidiol actif puis de l'acide correspondant. Le rendement réel de cette désacétylation chez l'humain n'a pas été mesuré.","detection":"Recherché en analyse de produits par chromatographie liquide ou gazeuse couplée à la spectrométrie de masse, dans le cadre du contrôle des liquides à vapoter et des aliments infusés. Il n'est pas ciblé par les dépistages toxicologiques de routine, et une exposition se traduirait principalement par la présence de cannabidiol et de ses métabolites.","subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":25},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":15},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":20},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":5},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":5}],"doseRanges":null,"humanDataCharacterised":true},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":false,"bannerTextFr":null,"toxicologyFr":"Aucune évaluation de sécurité n'a été conduite ni soumise. Le point de vigilance principal tient au mode de consommation observé plutôt qu'à une toxicité documentée : l'inhalation d'un ester chauffé n'a pas le même profil que son application cutanée, et l'expérience du THC-O-acétate a montré qu'un ester acétique de cannabinoïde peut, à la pyrolyse, engendrer un produit de dégradation problématique pour le poumon. Cette question n'a pas été étudiée pour le diacétate de cannabidiol."},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No control under the international conventions. The status of an acetylated derivative of cannabidiol in food or vaping falls under the regimes applicable to novel foods and vaping products, where the absence of assessment is the main obstacle: no safety dossier has been submitted for this compound.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"Cannabidiol is not a narcotic in France and its diacetate is named in no text. It falls neither under the heading of tetrahydrocannabinols and their esters, cannabidiol not being a tetrahydrocannabinol, nor under the generic clause targeting derivatives of the benzo[c]chromene core, a skeleton that cannabidiol does not possess. Its presence in consumer products does, however, raise a question of food safety and novel food regulation, distinct from narcotics law.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Chimie médicinale des dérivés synthétiques et naturels du cannabidiol (revue, Frontiers in Pharmacology 2017)","pmid":null,"doi":null,"url":"https://www.frontiersin.org/articles/10.3389/fphar.2017.00422/full"},{"label":"PubChem CID 15139512 : diacétate de cannabidiol","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/15139512"}],"meta":{"slug":"cbd-da","url":"https://en.phytogrammes.com/wiki/cbd-da","lastVerified":"2026-05-01","dataUpdatedAt":"2026-08-14","confidence":"medium","dataCompletenessPct":80,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}